Avalo Therapeutics, Inc. (AVTX) Stock Grade

About Avalo Therapeutics, Inc.'s fundamentals

Avalo Therapeutics is a small-cap biotechnology company with a market capitalization of $243.4 million that is currently unprofitable, having reported a significant net loss in its latest annual statement. The company experienced severe revenue contraction, declining 86.6% year-over-year, while maintaining a net margin of -132,642.4%, indicating operating expenses far exceed revenue generation. The company does not pay a dividend, and traditional profitability metrics like P/E ratio and return on equity are not applicable given its loss-making status. As an early-stage or troubled biotech firm, Avalo's financial performance reflects the challenges common to unprofitable development-stage companies.